-ThePrint.in At ThePrint’s Off The Cuff, WHO chief scientist Soumya Swaminathan sought to bust many myths around Covid-19, including its rumoured origin in a Wuhan lab. Bengaluru: A vaccine for the Covid-19 could emerge in about a year, World Health Organisation (WHO) chief scientist Soumya Swaminathan has said, even as she sought to highlight the possibility of the novel coronavirus becoming a seasonal virus like the influenza, or an endemic infection. In conversation...

-Hindustan Times With little transparency on how such deaths are investigated, and new rules relaxing how Clinical Trials are conducted in India, this data could be a poor estimate, said experts. Mumbai: At least 1,100 people who took part in Clinical Trials over the past four years have died, and 88 of these deaths were caused by direct side effects of the trials, the health ministry told the Rajya Sabha last week. But,...

-Deccan Chronicle Ayush ministry states that experience and evidence of effectiveness of these drugs is based on textual rationale and published in literature. Hyderabad: Fraudsters would flourish if patented or proprietary Ayruvedic, Siddha and Unani products are given licence without insisting on safety trials, industry experts and medical professionals have stated. The Centre has issued drug regulators in states a directive to issue licenses to patented and proprietary products of Ayurvedic, Siddha and...

-Livemint.com WHO says the Indian govt should ‘reconsider’ the compensation clause because an approval to the rules in the current form would affect the conduct of Clinical Trials in India New Delhi: The World Health Organization (WHO) has told the central government that the United Nations (UN) agency’s work with India would be “hampered” and drug companies driven away if the government goes ahead with stringent draft rules for compensation in case...

-The Times of India NEW DELHI: In a move to ensure efficacy of medicines sold in India, the drug regulator has made it mandatory for companies to include Indian patients in global Clinical Trials if they want to market in India a new drug developed outside the country. The decision was taken in a recent technical committee meeting, headed by director general of health services Jagdish Prasad. The committee, which was formed...